Open Access


Read more
image01

Online Manuscript Submission


Read more
image01

Submitted Manuscript Trail


Read more
image01

Online Payment


Read more
image01

Online Subscription


Read more
image01

Email Alert



Read more
image01

Original Research Article | OPEN ACCESS

Role of MiR-205/PTEN in cisplatin-resistant esophageal squamous cell carcinoma

Xun Tang1-3, Xuelian Mao1-3, Feng Yan1-3

1Jiangsu Cancer Hospital; 2Jiangsu Institute of Cancer Research; 3Department of Clinical Laboratory, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, 210009, China.

For correspondence:-  Feng Yan   Email: yanfengjiop@163.com

Accepted: 26 November 2018        Published: 26 December 2018

Citation: Tang X, Mao X, Yan F. Role of MiR-205/PTEN in cisplatin-resistant esophageal squamous cell carcinoma. Trop J Pharm Res 2018; 17(12):2347-2353 doi: 10.4314/tjpr.v17i12.5

© 2018 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To evaluate the effect of miRNA-205 on cisplatin-resistant TE13 cell lines, and the interaction of miRNA-205 with downstream signaling pathway.
Methods: TE13 cells were treated with cisplatin at a concentration of 1.5 μg/mL every 24 h for 3 months. Cisplatin-resistant cell lines were maintained in the continuous presence of 2 μg/ml cisplatin and supplemented every 72 h. Half-maximal inhibitory concentration (IC50) value was determined by MTT assay, and cell apoptosis was tested by flow cytometry. In addition, luciferase reporter assay was conducted to test the binding of miRNA-205 and phosphatase and tensin homologue deleted on chromosome 10 (PTEN) 3’UTR.
Results: The cisplatin-resistant (cis-TE13) cell line was well established based on IC50 values (cis-TE13, IC50 = 2.215; TE13, IC50 = 0.304). The levels of miRNA-205, phosphatase, PTEN, and protein kinase B (p-AKT) were abnormally expressed in cis-TE13 cells. Overexpression of miRNA-205 significantly promoted cell viability and decreased cell apoptosis of cis-TE13 cells as indicated by IC50 values (cis-TE13, IC50 = 3.537; TE13, IC50 = 0.580). Moreover, miRNA-205 significantly activated p-AKT expression by inhibiting PTEN expression. In contrast to miRNA-205, PTEN overexpression inhibited cell viability, increased cell apoptosis of cis-TE13 cells (cis-TE13, IC50 = 2.625; TE13, IC50 = 0.246), decreased the expression of p-AKT, and counteracted the regulation of miRNA-205 (control, IC50 = 2.297; miR-205, IC50 = 4.693; miR-205+PTEN, IC50 = 2.011).
Conclusion: These findings indicate that miRNA-205 exacerbates esophageal squamous cell carcinoma via inhibition of PTEN expression, suggesting the potential value of miRNA-205 in the diagnosis or treatment of esophageal squamous cell carcinoma.

Keywords: miRNA-205, PTEN, PI3K/AKT signaling pathway, Esophageal squamous cell, Carcinoma, Cisplatin resistance

Impact Factor
Thompson Reuters (ISI): 0.523 (2021)
H-5 index (Google Scholar): 39 (2021)

Article Tools

Share this article with



Article status: Free
Fulltext in PDF
Similar articles in Google
Similar article in this Journal:

Archives

2024; 23: 
1,   2,   3,   4
2023; 22: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2022; 21: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2021; 20: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2020; 19: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2019; 18: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2018; 17: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2017; 16: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2016; 15: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2015; 14: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2014; 13: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2013; 12: 
1,   2,   3,   4,   5,   6
2012; 11: 
1,   2,   3,   4,   5,   6
2011; 10: 
1,   2,   3,   4,   5,   6
2010; 9: 
1,   2,   3,   4,   5,   6
2009; 8: 
1,   2,   3,   4,   5,   6
2008; 7: 
1,   2,   3,   4
2007; 6: 
1,   2,   3,   4
2006; 5: 
1,   2
2005; 4: 
1,   2
2004; 3: 
1
2003; 2: 
1,   2
2002; 1: 
1,   2

News Updates